Bionano genomics inc news. Eric Holman, CEO. Investor Relations: David Holmes Gilmartin Group Oct 11, 2023 · Bionano announced today that it has priced a financing to raise an aggregate of $80. 's business for stockholders, potential investors, and financial analysts. The Investor Relations website contains information about Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first peer-reviewed benchmarking study to compare optical genome mapping (OGM) to the current global standard in molecular analysis of constitutional genetic disorders, chromosomal microarray analysis (CMA). (Nasdaq: BNGO) today announced the publication of a study of optical genome mapping (OGM) in hereditary breast and ovarian cancer (HBOC) syndrome showing that when tumors exhibited higher overall numbers of structural variations (SVs) they tended to have more mutated genes and altered signaling pathways, which may correlate Jul 6, 2021 · SAN DIEGO , July 06, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. The event is an opportunity for OGM users to present their progress to the world. (Nasdaq: BNGO) today announced the launch of Bionano Laboratories, a new organization that combines Bionano’s optical genome mapping (OGM) data services with the clinical testing services previously offered by Lineagen, and the launch of Bionano Laboratories’ first OGM-based laboratory developed test (LDT). bionano. Company Contact: Erik Holmlin, CEO Bionano Genomics, Inc. 0 million in a registered offering and concurrent private placement of senior secured convertible notes due 2025 and warrants Preliminary Q3 revenue expected to be between $9. 0 million aggregate principal Jun 9, 2022 · About Bionano Genomics, Inc. 06, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. 10,676,352 on June 9 th, 2020. (Nasdaq: BNGO), today announced the results of an implementation study conducted by researchers at University Medical Center Groningen that compared optical genome mapping (OGM) to traditional cytogenetic methods for the detection of structural variants (SVs) in bone marrow aspirate (BMA) samples. Bionano Genomics Investor Relations Contact: Ashley R. Jun 30, 2023 · Q2 2023 revenue was $8. 15%) As of 2:47 PM EDT. Source: Bionano Genomics Feb 6, 2019 · Bionano Genomics Contact: Mike Ward, CFO Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its 2024 Symposium, the quintessential event for the optical genome mapping (OGM) community. Common Stock (BNGO) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. misses on earnings expectations. BNGO stock quote prices, financial information, real-time forecasts, and company news from CNN. 97, moving -1. 03, 2024 (GLOBE NEWSWIRE) -- Bionano Laboratories, a laboratory services business of Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. (BNGO) stock. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. 's business for stockholders, potential Jan 19, 2024 · SAN DIEGO, Jan. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2023. 04, 2024 1:49 PM ET Bionano Genomics, Inc. $ Market cap P/E ratio $ Price 1d change 52-week range. The study also May 9, 2024 · Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the pricing of (i) $45. +1 (858) 888-7610 eholmlin@bionano. Find the latest Bionano Genomics, Inc. 26, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. 6 million in cash, cash equivalents, and available-for-sale securities as of YE 2021 Conference call today, March 1 st , 2022 at 4:30 PM ET SAN DIEGO , March Jan 10, 2024 · SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. VIA further incorporates these data Apr 24, 2024 · SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. Pioneering Innovations for Progress. 7 million , which represents a 30% increase over Q2 2022 Installed base of Saphyr ® systems totaled 281 as of June 30, 2023 , which represents a 43% increase over Q2 2022 Sold 7,062 nanochannel array flowcells as of June 30, 2023 , which represents a 108% increase over the Bionano Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules. Bionano Genomics ( NASDAQ: BNGO Apr 11, 2024 · SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. Investor Relations: David R. (Nasdaq: BNGO) today announced its participation in American Society of Human Genetics (ASHG) Annual Meeting 2022. He's joined by Gordon Thoma, CFO of Bionano. (Nasdaq: BNGO) announced today that Mayo Clinic has adopted the Saphyr system. 78%. Jun 29, 2023 · SAN DIEGO, June 29, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. Operator: Good day, and welcome to the Bionano First May 8, 2024 · Q1 2024 revenue was $8. +1 (858) 888-7600 mward@bionanogenomics. Investor Relations Contact: Company Contact: Erik Holmlin, CEO Bionano Genomics, Inc. (BNGO) today announced the conclusion of Bionano’s 2023 Symposium, which was held January 23-26, 2023 and featured a record 31 oral presentations and 69 scientific posters from genomic scientists at leading institutions, including Brigham and Women’s Hospital, The Mar 6, 2024 · Our installed base of optical genome mapping systems grew by 25% from the third to the fourth quarter of 2023 for a total of 326 on December 31st, 2023, which reflects a 36% increase from year-end Dec 28, 2023 · SAN DIEGO, Dec. (Nasdaq: BNGO) today announced the publication of a study from Penn State College of Medicine that used optical genome mapping Bionano Announces Three Publications Demonstrating OGM’s Utility for Cell and Gene Therapy. The study also Oct 26, 2023 · For the last reported quarter, it was expected that Bionano Genomics, Inc. 0 million aggregate principal amount of senior secured convertible notes due 2025 (the “Registered Notes”) and warrants (the “Registered Warrants”) to purchase 21,660,650 shares of its common stock in a registered offering, and (ii) $35. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™, the leading software solutions for visualization, interpretation and reporting of genomic data, today reported unaudited preliminary financial highlights for the Mar 31, 2023 · Bionano Genomics, Inc. 23, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) stock price, news, historical charts, analyst ratings and financial information from WSJ. The latest company information relevant to the individual and institutional investor includes stock price and history, upcoming Mar 1, 2022 · Full-year 2021 revenue growth of 111% over 2020 Achieved publicly announced anticipated milestones for 2021 Strong balance sheet with $250. (BNGO) closed the most recent trading day at $6. 28, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. Bionano Genomics Media Contact: Kirsten Thomas The Ruth Group +1 (508) 280-6592 kthomas@theruthgroup. 87. (Nasdaq: BNGO), today announced significant upgrades to its pipeline for analysis of optical genome mapping (OGM) data in its Apr 3, 2024 · SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. 8 million , which represents an 18% increase over Q1 2023 Total installed base of 347 optical genome mapping (OGM) systems as of Q1 2024, which represents a 34% increase over Q1 2023 Sold 8,249 nanochannel array flowcells in Q1 2024, which represents a 58% increase over the Nov 14, 2023 · SAN DIEGO, Nov. 30, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. +1 (858) 888-7610 eholmlin@bionanogenomics. Bionano to Report First Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 8, 2024. This move lagged the S&P 500's daily loss of 0. 12, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the publication of a study covering the analytical validation of its laboratory developed test (LDT), marketed as OGM-Dx™ HemeOne. Source: Bionano Genomics Dec 26, 2023 · SAN DIEGO, Dec. The firm engages in the development and marketing of May 15, 2024 · Bionano Genomics, Inc. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. Apr 22, 2024 · Bionano Announces Publication Showing that OGM Detects Over 1250 Structural Variants, including 56 Gene Fusions, in Pediatric Leukemia that were Missed by Whole Genome Sequencing. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. (NASDAQ:NASDAQ:BNGO) Q4 2023 Earnings Conference Call March 5, 2024 4:30 PM ETCompany ParticipantsDavid Holmes - Investor Apr 28, 2021 · Bionano Genomics, Inc. 02, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. 19, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc (Nasdaq: BNGO) today announced its 2024 Symposium lineup of 33 oral presentations delivered by 26 different customers worldwide featuring the utility of optical genome mapping (OGM) across a wide range of research applications in cancer, cell and gene therapy, and genetic Mar 7, 2024 · Bionano Genomics, Inc. (NASDAQ: BNGO) seeks to enhance shareholder value not only through exceptional business performance and practices, but also through responsible and effective communication with its shareholders. Apr. Reported EPS is $-0. Jan 12, 2022 · SAN DIEGO, Jan. Apr 11, 2024 · SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. 3 million, up 21% year-over-year. Bionano OGM solutions provide the essential tools clinicians and researchers need to reveal actionable insights from all classes of genomic variation. com. 8 million, an 18% year-over-year increase. (Nasdaq: BNGO) today announced a publication covering the largest independent prospective prenatal study comparing optical Mar 5, 2023 · Following the downgrade, the current consensus from Bionano Genomics' five analysts is for revenues of US$40m in 2023 which - if met - would reflect a huge 53% increase on its sales over the past May 9, 2023 · SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today Nov 1, 2023 · SAN DIEGO, Nov. (Nasdaq: BNGO) announced significant progress in China with the adoption of its Saphyr® System for optical genome mapping (OGM) by WeHealth Shanghai, a leading provider of genome analysis services in reproductive health. Media Contact: Darren Opland, PhD LifeSci Communications +1 (617) 733-7668 darren@lifescicomms. 24, delivering a surprise of -37. Bionano Genomics, Inc. GAAP SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. Investor Relations: David Holmes Gilmartin Group +1 (858) 888-7625 IR@bionano. The issue, which features guest editors Dr. 13% from the previous trading session. (Nasdaq: BNGO), today announced the publication of a special issue of Cancers journal entirely dedicated to the Company’s optical genome mapping (OGM) workflow. 09%. Mar 19, 2024 · SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. OGM has been shown to May 21, 2024 · SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the full commercial release of the Stratys™ system, the Company’s system for high throughput optical genome mapping (OGM). CONTACTS. May 21, 2024 · SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. As part of an early access program, the following 10 sites have adopted a total of 11 Stratys systems: A high-level overview of Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study from Penn State College of Medicine that used optical genome mapping (OGM) to search for clinically and biologically relevant genomic variations in pediatric B-cell acute lymphoblastic leukemia (B-ALL). All. The study highlighted OGM’s high analytical Jan 23, 2024 · SAN DIEGO, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™, the leading software solution for visualization, interpretation and reporting of genomic data, today announced the appointment of Aleks Rajkovic, MD, PhD, to its board of directors. 23, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that a study published in the journal Nature used Bionano’s genome imaging technology to establish one of the largest and most structurally accurate sets of genome data for a cohort of affected children and their parents in a study of the most May 28, 2024 · Bionano’s OGM products are for research use only and not for use in diagnostic procedures. For a description of these non-GAAP financial measures, please refer to “Non-GAAP Financial Measures”. Mark Ebbert brought the Saphyr system in-house after determining that Bionano’s technology can provide a deeper understanding of the genetic causes of neurodegenerative diseases and the routes to developing novel diagnostic Jun 8, 2020 · SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. ET on August 4, 2023. (BNGO) Stock ITP By: Nilanjana Basu, SA News Editor 8 Comments. GlobeNewswire Discover real-time Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation in the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting 2024 with a broad range of content covering optical genome mapping’s (OGM) utility for research areas including cancer, rare Oct 20, 2022 · SAN DIEGO, Oct. Bionano’s OGM products are for research use only and not for use in diagnostic procedures. (NASDAQ:BNGO) Q4 2023 Earnings Call Transcript March 5, 2024 Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that the United States Patent and Trademark Office will issue US Patent No. holmes@gilmartinir. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Holmes Gilmartin Group +1 (858) 366-3243 david. bionanolaboratories. (Nasdaq: BNGO) today announced the Stratys ™ system for high throughput optical genome mapping (OGM) and VIA ™ software for visualization, interpretation and reporting of genome analysis for OGM, microarrays and next-generation sequencing (NGS) data in one integrated software platform. SEC Filings. of BioDuro. 19, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. 28, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication covering the largest independent prospective prenatal study comparing optical genome mapping (OGM) to a combined workflow of chromosomal microarray analysis (CMA) and karyotyping (KT). 5 days ago · SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. 04, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. Mar 6, 2024 · Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation in the American Association for Cancer Research (AACR) Annual Meeting 2024 with a broad range of content covering the utility of OGM for cell bioprocessing quality control, solid tumor and hematological malignancy cancer Sep 28, 2023 · SAN DIEGO, Sept. (Nasdaq: BNGO) today announced that the American Society of Hematology (ASH) Annual Meeting and Exposition 2023 will feature a broad range of content covering OGM’s utility for research in areas including myeloid cancer, hematological malignancy, leukemia and blood disorders. The effective time of the reverse stock split will be 5 p. The patent, titled “NANONOZZLE DEVICE ARRAYS: THEIR PREPARATION AND USE FOR MACROMOLECULAR ANALYSIS,” covers the addition of a detector, such as a nanopore, to Bionano’s patented Get the latest BioNano Genomics Inc (BNGO) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. 3 million , which would Jan 30, 2024 · SAN DIEGO, Jan. (Nasdaq: BNGO) today announced the Company’s robust participation at two upcoming cytogenetics conferences, the 2024 European Society for Human Genetics (ESHG) Annual Conference and the 2024 American Cytogenomics Conference (ACC), with a record 39 scientific presentations and Sep 30, 2021 · SAN DIEGO, Nov. Eastern Time to report financial results for the third quarter 2023 and to highlight recent corporate progress. View All Releases. Bionano Announces Robust Presence at Upcoming Cytogenetics Find the latest Bionano Genomics, Inc. This LDT is based on optical genome mapping (OGM) analysis of blood or bone marrow Company profile page for Bionano Genomics Inc including stock price, company news, executives, board members, and contact information Feb 2, 2023 · SAN DIEGO, Feb. (BNGO), today announced the publication of three studies which collectively illustrate the continued development of data supporting the utility of optical genome mapping (OGM) in cell and gene therapy applications. (BNGO) today announced the conclusion of Bionano’s 2024 Symposium, the quintessential event for the optical genome mapping (OGM) community, which was held January 22-25, 2024, and featured a record 32 oral presentations and 69 scientific posters from genomic scientists at Mar 7, 2024 · SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study of optical genome mapping (OGM) in hereditary breast and ovarian cancer (HBOC) syndrome showing that when tumors exhibited higher overall numbers of structural variations (SVs) they tended to have more mutated genes and altered signaling pathways, which may correlate Apr 4, 2024 · Bionano Genomics. Press Releases. Would post a loss of $0. Mar 7, 2022 · SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. May 9, 2024 · A: Gulsen Kama - Bionano Genomics Inc - Chief Financial Officer: In Q1 2024, revenue was $8. The firm engages in the development and marketing of the Saphyr system, a platform Oct 11, 2023 · SAN DIEGO, Oct. For the first time, ASHG will feature a dedicated scientific session on genome mapping technologies, with researchers highlighting optical genome mapping (OGM) as Aug 24, 2020 · Bionano Genomics, Inc. Jan 23, 2024 · SAN DIEGO, Jan. News. Apr 2, 2024 · SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. com or www. Sep 23, 2022 · SAN DIEGO, Sept. Bionano OGM Mapping Systems—Provide the data other tools miss with digital precision in a rapid, highly automated workflow from sample preparation through May 15, 2024 · Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, November 8, 2023, at 4:30 p. About BNGO. A team led by Dr. 90 per share when it actually produced a loss of $1. After market Mar 6, 2024 · Bionano Genomics, Inc. Leading the call today is Dr. 0015 (+0. 9845 +0. Robinson LifeSci Advisors, LLC +1 (617) 775-5956 arr@lifesciadvisors. 30 Apr '24. (Nasdaq: BNGO) today announced the publication of a study of optical genome mapping (OGM) in hereditary breast and ovarian Bionano will host a pre-conference scientific session that will include a live product demonstration of the Stratys system for high throughput optical View the latest Bionano Genomics Inc. 7 million , which represents a 30% increase over Q2 2022 Installed base of Saphyr ® systems totaled 281 as of June 30, 2023 , which represents a 43% increase over Q2 2022 Sold 7,062 nanochannel array flowcells as of June 30, 2023 , which represents a 108% increase over the SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today reported financial results and business achievements for the quarter ended September 30, 2021 and highlighted recent corporate updates. Bionano Announces Series of Major Advancements to its Suite of Computational Tools for Comprehensive Cancer Analysis. Q1 2023 Highlights Apr 4, 2024 · Bionano announces $10M registered direct offering. Apr 24, 2024 · SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) stock quote, history, news and other vital information to help you with your stock trading and investing. Bionano Announces Three Publications Demonstrating OGM’s Utility for Cell and Gene Therapy. View Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the full commercial release of the Stratys™ system, the Company’s system for high throughput Aug 9, 2023 · Q2 2023 revenue was $8. Market Open. Feb 28, 2024 · - Amendment Reduces Bionano’s Outstanding Debt - SAN DIEGO, Feb. Stay ahead with Nasdaq. Investor Relations Contact: Ashley R. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics , Inc. Dec 6, 2023 · SAN DIEGO, Dec. (“Bionano”) (Nasdaq: BNGO) today announced that is has amended the convertible debt financing the company entered into in October 2023 pursuant to which the company agreed to issue and sell to a certain accredited investor (the “Buyer”) (i) in a registered offering by Apr 11, 2024 · SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. 10, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has entered into definitive agreements for the purchase and sale of an Dec 14, 2023 · SAN DIEGO , Dec. Robinson LifeSci Advisors, LLC +1 (617) 430-7577 arr@lifesciadvisors. Core revenues were $7. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. 8 million , which represents an 18% increase over Q1 2023 Total installed base of 347 optical genome mapping (OGM) systems as of Q1 2024, which represents a 34% increase over Q1 2023 Sold 8,249 nanochannel array flowcells in Q1 2024, which represents a 58% increase over the Dec 12, 2023 · SAN DIEGO , Dec. (BNGO) 0. Bionano to Present at the RBC Capital Markets 2024 Global Healthcare Conference. In all three publications, the authors note OGM’s potential to provide a comprehensive landscape of genome Bionano Genomics Company Info. purigenbio. com, www. (NASDAQ: BNGO) today announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-10. (NASDAQ:NASDAQ:BNGO) Q4 2023 Earnings Conference Call March 5, 2024 4:30 PM ETCompany ParticipantsDavid Holmes - Investor . 1 and $9. 1 Non-GAAP gross margin and non-GAAP operating expense are non-GAAP financial measures. View the latest Bionano Genomics Inc. Dec 19, 2019 · SAN DIEGO, Dec. Jul 23, 2020 · SAN DIEGO, July 23, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of the first framework paper for the clinical adoption and implementation of the optical genome mapping (OGM) workflow for hematological malignancy applications, a process May 15, 2024 · 01 May '24. com May 9, 2024 · Welcome to the Bionovo first quarter 2024 financial results conference call. The latest company information relevant to the individual and institutional investor includes stock price and history, upcoming Apr 24, 2024 · SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. 2024 Symposium will feature four consecutive days of OGM presentations Dec 26, 2023 · SAN DIEGO, Dec. Aug 1, 2023 · SAN DIEGO , Aug. 96 EPS, expectations were $-0. May 8, 2024 · Q1 2024 revenue was $8. Mar 9, 2023 · About Bionano Genomics Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. m. Jan 3, 2024 · SAN DIEGO, Jan. (Nasdaq: BNGO), today announced the publication of a peer-reviewed study that compared optical genome mapping (OGM) to classical cytogenetic techniques used for analysis of solid tumor cancer samples consisting of soft tissue and bone sarcomas, including fluorescence in situ hybridization (FISH) and karyotyping (KT). In all three publications, the authors note OGM’s potential to BNGO Competitors. 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation in the Association for Molecular Pathology (AMP) 2023 Annual Meeting and Expo with a broad range of content covering the utility of optical genome mapping (OGM) for cell and gene therapy and cancer research, including scientific Jan 31, 2024 · For more information, visit www. 12, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. qx qk vm xl to fl xo zp ml wd